Mirum Pharmaceuticals, Inc. (MIRM)

Mirum Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-23.36	-87.94	-163.42	-135.67	-83.99
Depreciation & Amortization	24.24	23.63	10.83	3.24	0.6
Stock-Based Compensation	71.42	48.44	35.02	27.01	23.09
Other Adjustments	3.24	3.6	65.84	6.33	-89.44
Change in Receivables	-48.06	-11.43	-43.97	-20.73	-
Changes in Inventories	-8.45	-3.17	-0.97	-3.44	-0.5
Changes in Accrued Expenses	50.1	40.31	30.78	7.63	22.92
Changes in Other Operating Activities	-13.32	-3.13	-5.05	-4.51	-5.18
Operating Cash Flow	55.83	10.33	-70.94	-120.14	-132.76
Operating Cash Flow Growth	440.70%	-	-	-	-
Capital Expenditures	-0.95	-0.99	-0.11	-0.28	-0.02
Purchases of Intangible Assets	-20	-20	-	-	-19
Purchases of Investments	-97.43	-89.03	-27.33	-132.32	-198.03
Proceeds from Sale of Investments	74.43	19.89	153	140.3	157.6
Payments for Business Acquisitions	-	-	-212.76	-	-
Other Investing Activities	-	-	-	-	108
Investing Cash Flow	-23.95	-90.13	-107.2	7.7	48.55
Long-Term Debt Issued	-	-	305.3	-	-
Net Long-Term Debt Issued (Repaid)	-	-	305.3	-	-
Issuance of Common Stock	40.14	17.7	227.15	114.64	9.01
Net Common Stock Issued (Repurchased)	40.14	17.7	227.15	114.64	9.01
Other Financing Activities	-	-	-195.86	-5.55	64.45
Financing Cash Flow	40.14	17.7	336.6	109.09	73.47
Effect of Exchange Rate Changes on Cash and Cash Equivalents	3.22	-1.3	-0.13	0.01	-
Net Cash Flow	75.24	-63.4	158.32	-3.34	-10.75
Free Cash Flow	54.87	9.33	-71.05	-120.41	-132.78
Free Cash Flow Growth	488.01%	-	-	-	-
FCF Margin	10.53%	2.77%	-38.12%	-156.26%	-693.81%
Free Cash Flow Per Share	1.09	0.20	-1.74	-3.54	-4.38
Levered Free Cash Flow	28.27	-31.29	177.36	-133.03	-66.17
Unlevered Free Cash Flow	27.49	-31.99	-74.35	-122.67	-155.67

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q